GlassScriptPhysician profile
Brian P Kelty
NPI 1124462221
$4,273.94
in general payments reported to CMS, 2019-2025
35 companies · $879 in 2025
The $879 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $83.03 · 2021: $743 · 2022: $349 · 2023: $926 · 2024: $727 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,531.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $635.18 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $582.62 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Neuronetics, INC. | $509.29 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $483.11 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $254.81 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $205.32 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $161.59 | 2022-2024 | Jornay Pm |
| Alkermes, INC. | $134.71 | 2022-2025 | Aristada, Lybalvi |
| Corium, LLC | $127.13 | 2021-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $110.76 | 2024-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $98.19 | 2022-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $89.01 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $83.62 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $65.87 | 2025 | Jornay Pm |
| Amgen INC. | $65.62 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.88 | 2021 | |
| Tris Pharma INC | $58.75 | 2023 | Dyanavel Xr |
| Exact Sciences Corporation | $56.39 | 2023 | Cologuard Collection Kit |
| Neos Therapeutics, LP | $56.28 | 2023-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Lundbeck LLC | $56.14 | 2022-2024 | Rexulti |
| Allergan, INC. | $53.26 | 2019-2020 | |
| Novo Nordisk INC | $51.26 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $39.51 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $35.53 | 2021 | |
| Sage Therapeutics, LLC | $30.84 | 2025 | Zurzuvae |
| Acadia Pharmaceuticals INC | $25.95 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $19.47 | 2025 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $17.86 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.42 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $15.35 | 2023 | Xelstrym |
| Neurocrine Biosciences, INC. | $15.24 | 2025 | |
| Abbott Laboratories | $14.47 | 2021 | |
| Merck Sharp & Dohme LLC | $14.47 | 2020 | |
| Eisai INC. | $14.14 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kelty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.